Search

The development of UAV sensors has made it possible to obtain a diverse array of spectral images in a single flight. In this study, high-resolution UAV-derived images of urban areas were employed to create land cover maps, including car-road, sidewalk, and street vegetation. A total of nine orthoimages were produced, and the variables effective in producing UAV-based land cover maps were identified. Based on analyses of the object-based images, 126 variables were derived by computing 14 statistical values for each image. The random forest (RF) classifier was used to evaluate the priority of the 126 variables. This was followed by optimizing the RF through variable reduction and by comparing the initial and optimized RF, the utility of the high-priority variable was evaluated. Computing variable importance, the most influential variables were evaluated in the order of normalized digital surface model (nDSM), normalized difference vegetation index (NDVI), land surface temperature (LST), soil adjusted vegetation index (SAVI), blue, green, red, rededge. Finally, no significant changes between initial and optimized RF in the classification were observed from a series of analyses even though the reduced variables number was applied for the classification.

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder of lipoprotein metabolism that leads to an increased risk of developing atherosclerosis and coronary artery disease. Hypercholesterolemia in pediatric patients is typically due to FH. Treatment of pediatric FH is achieved through lifestyle modifications, lipid-modifying pharmacotherapy, and/or apheresis. The primary objective of this review is to describe the characteristics of clinical trials conducted in pediatric patients with FH with data submitted to the US Food and Drug Administration from 2007 to 2020. Of 10 trials with 8 products in pediatric FH submitted to the Food and Drug Administration, 1 product was studied in both the heterozygous and the homozygous phenotypes, 5 were studied for heterozygous hypercholesterolemia only, and 2 were studied for homozygous familial hypercholesterolemia only. Most of the trials included pediatric patients =10 years of age and older. Clinical trial characteristics including the primary efficacy end points between pediatric and adult trials were mostly identical. Many lipid-lowering drugs with novel mechanisms of action have been recently approved or are currently being studied. In summary, the drug treatment of hypercholesterolemia in pediatric patients is expanding beyond the use of statins, and now involves multiple mechanisms of action involving cholesterol metabolism. As younger pediatric patients are diagnosed and treated for heterozygous familial hypercholesterolemia and homozygous familial hypercholesterolemia, optimizing the doses of these agents and safety studies specific to younger pediatric patients will be necessary. [ABSTRACT FROM AUTHOR]